Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Argus Health
Chinese Patent Office
Covington
Julphar
Teva
Colorcon
Farmers Insurance

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,375,972

« Back to Dashboard

Summary for Patent: 6,375,972
Title: Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Abstract:A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.
Inventor(s): Guo; Hong (Bellmont, MA), Ashton; Paul (Boston, MA)
Assignee: Control Delivery Systems, Inc. (Watertown, MA)
Application Number:09/558,207
Patent Claim Types:
see list of patent claims
Delivery; Use; Device;

Drugs Protected by US Patent 6,375,972

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF DIABETIC MACULAR EDEMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,375,972

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,566,336 In situ gelling drug delivery system ➤ Sign Up
8,574,659 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof ➤ Sign Up
8,815,284 Bioerodible sustained release drug delivery systems ➤ Sign Up
7,439,249 Inhibitors of phosphatases ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fuji
Harvard Business School
Argus Health
US Army
Boehringer Ingelheim
Teva
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.